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Transl Lung Cancer Res 2018 tlcr.amegroups.com patients and has shown some value for predicting response to immune checkpoint inhibitors in some studies, but not in others. The use of PD-L1 as a biomarker remains to be complicated by a number of factors including the variability in tissue collection timing, the antibody and methodology used for staining (including the definition of positivity and the non-standardised test design), the heterogeneity and dynamic of PD-L1 expression within different tumours, and the role of PD-L1 expression on tumour-infiltrating lymphocytes and other immune cells versus the malignant cell population. In addition, PD-L1 is regarded to be a biological continuum and therefore might be of limited value as a biomarker in this subset of patients (2) .
Pembrolizumab (Keytruda ® , Merck, USA: targeting PD-1) is approved (EMA, FDA) for first-line treatment of NSCLC patients with advanced or metastatic cancers (with PD-L1 expression ≥50% using the Dako 22C3 IHC assay), whereas for second-line treatment a PD-L1 expression of ≥1% is required (1) . Both, nivolumab (Opdivo ® , Bristol-Myers Squibb, USA: targeting PD-1) and atezolizumab (Tecentriq ® , Roche, Switzerland: targeting PD-L1) are also approved (EMA, FDA) in the second-line setting, but PD-L1 screening is not mandatory, however, complementary PD-L1 diagnostics are approved for NSCLC (1) . Durvalumab (Imfinzi ® , AstraZeneca, UK: targeting PD-L1) and avelumab (Bavencio ® , MerckSerono, Germany: targeting PD-L1) are currently evaluated in first-or second-line treatment studies for NSCLC and are not approved for NSCLC treatment yet. However, it should be noted that durvalumab has demonstrated a significant progression-free survival (PFS) benefit [16.8 versus 5.6 months, hazard ratio (HR) =0.52] as maintenance therapy in stage IIIA/B NSCLC patients following radio-chemotherapy and two cycles of platinumbased therapy (PACIFIC trial) (3). Interestingly, PFS benefit was independent of PD-L1 expression. Details of this relevant phase III study is given in Table 1 .
Some clinical trials ( Table 1 ) have demonstrated that PD-L1 expression appears to be significantly correlated with clinical outcomes in NSCLC, but not in all trials, although some patients treated in these trials who had PD-L1-negative lung cancers, clinical benefit from PD-1/PD-L1 inhibitors was also observed. This observation adds therefore weight to the proposal that PD-L1 is a weak biomarker which prompted researchers to look beyond PD-L1 expression levels in order to identify more robust predictive biomarkers which then could help to better identify the immune status and the pre-existing tumour microenvironment of a given tumour.
To date, many groups of oncologists are attempting to establish better predictive biomarkers in NSCLC for monoclonal antibodies targeting the PD-1/PD-L1 axis to select patients who might have a greater benefit from immune checkpoint therapies. Initial preclinical and clinical studies have revealed that tumour mutational burden (TMB) or gene signatures may be an ideal strategy guiding treatment decisions for checkpoint inhibitors (15, 16) . Yarchoan et al. (15) reported a clear correlation between TMB and overall response rate (ORR) (P<0.001) following checkpoint inhibitor treatment in many cancers suggesting that a significant relationship between TMB and anti-PD-1/ anti-PD-L1 treatment exists. On the other hand, Leal and Ramalingham (1) found that in NSCLC patients responding to immune checkpoint inhibitor treatment early PD-L1positive CD8-positive T cell responses were seen suggesting that these proliferating CD8-positive T cells may have an effector-like phenotype which could generate cytotoxicity [see also (16) for a review].
Most recently, two phase III studies (CheckMate-227 and IMPower 150) have provided evidence that TMB correlates with the clinical response to the combination of nivolumab and ipilimumab (Yervoy ® , Bristol-Myers Squibb, USA: targeting CTLA-4) (CheckMate-227) (12), whereas atezolizumab response was correlated with T effector gene signature expression (IMPower 150) (5, 6, 16) . Both studies were conducted as first-line trials in NSCLC ( Table 1) . The CheckMate-227 trial is the first to our knowledge to evaluate TMB as a predictive biomarker for immunotherapy in NSCLC (co-primary endpoint). The study demonstrated a significant PFS benefit in the nivolumab + ipilimumab group in first-line NSCLC patients with a TMB level of ≥10 mutation/Mbase regardless of PD-L1 expression (7.2 versus 5.5 months, HR=0.58, P<0.001) (12) . Interestingly, the reported median PFS benefit was only seen in the TMB subgroup, but not the overall population (12) suggesting that TMB may be a predictive novel biomarker for checkpoint inhibitor treatment. Objective response rates were found to be 45.3% versus 26.9%, respectively (12) .
The IMPower 150 trial is the first phase III study to demonstrate a clinically meaningful and significant PFS benefit with atezolizumab plus bevacizumab and chemotherapy (paclitaxel and carboplatin) versus bevacizumab plus chemotherapy in the first-line stetting of advanced or metastatic NSCLC (8.3 versus 6.8 months, HR=0.62, P<0.0001) and the PFS benefit was seen regardless of the PD-L1 status in all patients (5, 11) . The PFS benefit, however, was even more pronounced in patients expressing a T effector gene signature (11.3 versus 6.8 months, HR=0.51, P<0.0001) (5, 6) indicative that the expression of gene signatures may be more robust to predict clinical response following treatment with PD-L1 inhibitors.
Although PD-L1 testing has clearly some limitations as a predictive biomarker, it is currently widely used (17) . Despite progress made so far in terms of novel immunotherapy strategies for NSCLC, the major challenge still remains to identify those patients with advanced or metastatic NSCLC who will benefit the most following treatment with immune checkpoint inhibitors. In this regard the role of the putative novel predictive biomarkes evaluated in the CheckMate-227 and in the IMPower 150 trials may, if confirmed in further prospective clinical trials, offer a new perspective for predicting immunotherapy treatment outcomes of NSCLC patients in the near future.
